Tags

Type your tag names separated by a space and hit enter

Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
Hum Reprod 2001; 16(11):2258-62HR

Abstract

BACKGROUND

The aim of our study was to explore luteal phase hormone profiles in gonadotrophin-stimulated cycles with or without gonadotrophin-releasing hormone (GnRH) antagonist therapy during intrauterine insemination (IUI). Forty-one infertile couples were recruited in this randomized clinical study.

METHODS

The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of > or =14 mm was seen at ultrasound scan. Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration. The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles.

RESULTS

The two treatment groups showed a similar increase in progesterone concentration during the luteal phase. In the mid-luteal phase (day 6 after HCG), oestradiol concentrations in group B were significantly higher compared with group A (P < 0.05) but the oestradiol:progesterone ratio was similar in the two groups. Serum LH was completely suppressed during the follicular phase only in group A, concomitantly with GnRH antagonist administration. A total of six pregnancies, all ongoing, were achieved (14.3% per patient and 12.2% per cycle), equally distributed in group A and in group B.

CONCLUSION

GnRH antagonists can be safely administered in gonadotrophin-stimulated IUI cycles without luteal phase supplementation because no deleterious effects of GnRH antagonist administration were noted on luteal progesterone concentration or on the duration of the luteal phase.

Authors+Show Affiliations

Infertility Unit, Department of Obstetrics and Gynaecology, University of Milan, Via Manfredo Fanti 6, 20122 Milan, Italy. ragni@telemacus.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

11679500

Citation

Ragni, G, et al. "Comparison of Luteal Phase Profile in Gonadotrophin Stimulated Cycles With or Without a Gonadotrophin-releasing Hormone Antagonist." Human Reproduction (Oxford, England), vol. 16, no. 11, 2001, pp. 2258-62.
Ragni G, Vegetti W, Baroni E, et al. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Hum Reprod. 2001;16(11):2258-62.
Ragni, G., Vegetti, W., Baroni, E., Colombo, M., Arnoldi, M., Lombroso, G., & Crosignani, P. G. (2001). Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Human Reproduction (Oxford, England), 16(11), pp. 2258-62.
Ragni G, et al. Comparison of Luteal Phase Profile in Gonadotrophin Stimulated Cycles With or Without a Gonadotrophin-releasing Hormone Antagonist. Hum Reprod. 2001;16(11):2258-62. PubMed PMID: 11679500.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. AU - Ragni,G, AU - Vegetti,W, AU - Baroni,E, AU - Colombo,M, AU - Arnoldi,M, AU - Lombroso,G, AU - Crosignani,P G, PY - 2001/10/27/pubmed PY - 2002/1/12/medline PY - 2001/10/27/entrez SP - 2258 EP - 62 JF - Human reproduction (Oxford, England) JO - Hum. Reprod. VL - 16 IS - 11 N2 - BACKGROUND: The aim of our study was to explore luteal phase hormone profiles in gonadotrophin-stimulated cycles with or without gonadotrophin-releasing hormone (GnRH) antagonist therapy during intrauterine insemination (IUI). Forty-one infertile couples were recruited in this randomized clinical study. METHODS: The 19 patients included in group A were treated for 21 cycles with recombinant FSH 150 IU/day starting from day 3 of the cycle and with the GnRH antagonist cetrorelix at the dose of 0.25 mg/day starting from the day in which a follicle with a mean diameter of > or =14 mm was seen at ultrasound scan. Cetrorelix was administered until human chorionic gonadotrophin (HCG) administration. The 22 patients included in group B were administered recombinant FSH alone at the same dosage for 27 cycles. RESULTS: The two treatment groups showed a similar increase in progesterone concentration during the luteal phase. In the mid-luteal phase (day 6 after HCG), oestradiol concentrations in group B were significantly higher compared with group A (P < 0.05) but the oestradiol:progesterone ratio was similar in the two groups. Serum LH was completely suppressed during the follicular phase only in group A, concomitantly with GnRH antagonist administration. A total of six pregnancies, all ongoing, were achieved (14.3% per patient and 12.2% per cycle), equally distributed in group A and in group B. CONCLUSION: GnRH antagonists can be safely administered in gonadotrophin-stimulated IUI cycles without luteal phase supplementation because no deleterious effects of GnRH antagonist administration were noted on luteal progesterone concentration or on the duration of the luteal phase. SN - 0268-1161 UR - https://www.unboundmedicine.com/medline/citation/11679500/Comparison_of_luteal_phase_profile_in_gonadotrophin_stimulated_cycles_with_or_without_a_gonadotrophin_releasing_hormone_antagonist_ L2 - https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/16.11.2258 DB - PRIME DP - Unbound Medicine ER -